140 lines
34 KiB
Text
140 lines
34 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK612279">
|
|
<meta name="ncbi_domain" content="ukeme1201">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK612279/?report=reader">
|
|
<meta name="ncbi_pagename" content="The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="jr-next-unit" content="/books/n/ukeme1201/toc/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/ukeme1201/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="Kymberley Carter, Wai-Yee Cheung, Hayley A Hutchings, Greg Fegan, Gail Holland, Steve Luzio, Gareth Dunseath, Stephen Hiles, Susie Marques-Jones, John W Gregory, Danijela Tatovic, Peter Taylor, Jane Bowen-Morris, Rachel Stenson, Stephanie Hanna, Zainab Mahmood, Jennie Yang, Evangelia Williams, Timothy Tree, Ashish Marwaha, Colin M Dayan">
|
|
<meta name="citation_title" content="The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Research">
|
|
<meta name="citation_date" content="2025/02">
|
|
<meta name="citation_author" content="Kymberley Carter">
|
|
<meta name="citation_author" content="Wai-Yee Cheung">
|
|
<meta name="citation_author" content="Hayley A Hutchings">
|
|
<meta name="citation_author" content="Greg Fegan">
|
|
<meta name="citation_author" content="Gail Holland">
|
|
<meta name="citation_author" content="Steve Luzio">
|
|
<meta name="citation_author" content="Gareth Dunseath">
|
|
<meta name="citation_author" content="Stephen Hiles">
|
|
<meta name="citation_author" content="Susie Marques-Jones">
|
|
<meta name="citation_author" content="John W Gregory">
|
|
<meta name="citation_author" content="Danijela Tatovic">
|
|
<meta name="citation_author" content="Peter Taylor">
|
|
<meta name="citation_author" content="Jane Bowen-Morris">
|
|
<meta name="citation_author" content="Rachel Stenson">
|
|
<meta name="citation_author" content="Stephanie Hanna">
|
|
<meta name="citation_author" content="Zainab Mahmood">
|
|
<meta name="citation_author" content="Jennie Yang">
|
|
<meta name="citation_author" content="Evangelia Williams">
|
|
<meta name="citation_author" content="Timothy Tree">
|
|
<meta name="citation_author" content="Ashish Marwaha">
|
|
<meta name="citation_author" content="Colin M Dayan">
|
|
<meta name="citation_pmid" content="39999241">
|
|
<meta name="citation_doi" content="10.3310/FQLN7416">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK612279/">
|
|
<meta name="citation_keywords" content="DIABETES MELLITUS TYPE 1">
|
|
<meta name="citation_keywords" content="RANDOMISED CONTROLLED TRIAL">
|
|
<meta name="citation_keywords" content="USTEKINUMAB">
|
|
<meta name="citation_keywords" content="C-PEPTIDE">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Research">
|
|
<meta name="DC.Contributor" content="Kymberley Carter">
|
|
<meta name="DC.Contributor" content="Wai-Yee Cheung">
|
|
<meta name="DC.Contributor" content="Hayley A Hutchings">
|
|
<meta name="DC.Contributor" content="Greg Fegan">
|
|
<meta name="DC.Contributor" content="Gail Holland">
|
|
<meta name="DC.Contributor" content="Steve Luzio">
|
|
<meta name="DC.Contributor" content="Gareth Dunseath">
|
|
<meta name="DC.Contributor" content="Stephen Hiles">
|
|
<meta name="DC.Contributor" content="Susie Marques-Jones">
|
|
<meta name="DC.Contributor" content="John W Gregory">
|
|
<meta name="DC.Contributor" content="Danijela Tatovic">
|
|
<meta name="DC.Contributor" content="Peter Taylor">
|
|
<meta name="DC.Contributor" content="Jane Bowen-Morris">
|
|
<meta name="DC.Contributor" content="Rachel Stenson">
|
|
<meta name="DC.Contributor" content="Stephanie Hanna">
|
|
<meta name="DC.Contributor" content="Zainab Mahmood">
|
|
<meta name="DC.Contributor" content="Jennie Yang">
|
|
<meta name="DC.Contributor" content="Evangelia Williams">
|
|
<meta name="DC.Contributor" content="Timothy Tree">
|
|
<meta name="DC.Contributor" content="Ashish Marwaha">
|
|
<meta name="DC.Contributor" content="Colin M Dayan">
|
|
<meta name="DC.Date" content="2025/02">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK612279/">
|
|
<meta name="description" content="Type 1 diabetes is an autoimmune disease affecting over 400,000 children and adults in the United Kingdom for which currently the only available therapy is insulin.">
|
|
<meta name="og:title" content="The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Type 1 diabetes is an autoimmune disease affecting over 400,000 children and adults in the United Kingdom for which currently the only available therapy is insulin.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK612279/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-ukeme1201-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/ukeme1201/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK612279/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C47BD7C8D92410000000000060005.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK612279/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK612279/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK612279/&text=The%20efficacy%20and%20safety%20of%20ustekinumab%20in%20adolescents%20newly%20diagnosed%20with%20type%201%20diabetes%3A%20the%20USTEK1D%20RCT"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/ukemecollect/?report=reader">Efficacy and Mechanism Evaluation</a><a class="current">Title Information</a><a href="/books/n/ukeme1201/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK612279/?report=classic">Switch to classic view</a><a href="/books/n/ukeme1201/pdf/">PDF (2.3M)</a><a href="/books/n/ukeme1201/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK612279%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C47BD7C8D92410000000000060005.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="http://www.journalslibrary.nihr.ac.uk/eme" title="National Institute for Health and Care Research" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-ukeme1201-lrg.png" alt="Cover of The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT" /></a></div><div class="bkr_bib"><h1 id="_NBK612279_"><span itemprop="name">The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT</span></h1><p><i>Efficacy and Mechanism Evaluation, No. 12.01</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Kymberley Carter</span>,<sup>1</sup> <span itemprop="author">Wai-Yee Cheung</span>,<sup>2</sup> <span itemprop="author">Hayley A Hutchings</span>,<sup>1</sup> <span itemprop="author">Greg Fegan</span>,<sup>1</sup> <span itemprop="author">Gail Holland</span>,<sup>1</sup> <span itemprop="author">Steve Luzio</span>,<sup>2</sup> <span itemprop="author">Gareth Dunseath</span>,<sup>2</sup> <span itemprop="author">Stephen Hiles</span>,<sup>1</sup> <span itemprop="author">Susie Marques-Jones</span>,<sup>3</sup> <span itemprop="author">John W Gregory</span>,<sup>4</sup> <span itemprop="author">Danijela Tatovic</span>,<sup>5</sup> <span itemprop="author">Peter Taylor</span>,<sup>5</sup> <span itemprop="author">Jane Bowen-Morris</span>,<sup>5</sup> <span itemprop="author">Rachel Stenson</span>,<sup>5</sup> <span itemprop="author">Stephanie Hanna</span>,<sup>5</sup> <span itemprop="author">Zainab Mahmood</span>,<sup>5</sup> <span itemprop="author">Jennie Yang</span>,<sup>6</sup> <span itemprop="author">Evangelia Williams</span>,<sup>6</sup> <span itemprop="author">Timothy Tree</span>,<sup>6</sup> <span itemprop="author">Ashish Marwaha</span>,<sup>7</sup> and <span itemprop="author">Colin M Dayan</span><sup>5</sup><sup>,*</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Swansea Trials Unit (STU), Swansea University Medical School, Singleton Park, Swansea, UK</div><div class="affiliation"><sup>2</sup> Diabetes Research Unit Cymru (DRUC, now known as Diabetes Research Group), Grove Building, Swansea University College of Medicine, Singleton Park, Swansea, UK</div><div class="affiliation"><sup>3</sup>
|
|
|
|
Public and patient involvement (PPI) representative
|
|
</div><div class="affiliation"><sup>4</sup> Division of Population Medicine, Cardiff University School of Medicine, Heath Park, Cardiff, UK</div><div class="affiliation"><sup>5</sup> Division of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK</div><div class="affiliation"><sup>6</sup> Department of Immunobiology, King’s College London, Guy’s Hospital, London, UK</div><div class="affiliation"><sup>7</sup> Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada</div><div class="affiliation"><sup>*</sup> Corresponding author<span class="before-email-separator">; </span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.ffidrac@mcnayad" class="oemail">ku.ca.ffidrac@mcnayad</a></div><div class="half_rhythm">Southampton (UK): <a href="http://www.journalslibrary.nihr.ac.uk/eme" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Research</span></a>; <span itemprop="datePublished">2025 Feb</span>.</div><div><a href="/books/about/copyright/">Copyright</a> © 2025 Carter <i>et al</i>.</div><a class="btn wsprkl bkr_rd" href="/books/n/ukeme1201/abs3/?report=reader">Read</a></div><div class="bkr_clear"></div></div><div class="bkr_bottom_sep bkr_bottom_margin body-content whole_rhythm"><div itemprop="description"><h2>Abstract</h2><div id="abs1-1"><h4 class="inline">Background:</h4><p>Type 1 diabetes is an autoimmune disease affecting over 400,000 children and adults in the United Kingdom for which currently the only available therapy is insulin.</p></div><div id="abs1-2"><h4 class="inline">Objective(s):</h4><p>To determine the efficacy and safety of the monoclonal antibody ustekinumab targeting the interleukin 12/interleukin 23 immune pathway that generates T helper 1/T helper 17 T cells to slow down the autoimmune process and preserve beta cell production in type 1 diabetes.</p></div><div id="abs1-3"><h4 class="inline">Design:</h4><p>Randomised, double-blind, placebo-controlled, parallel-group phase II trial.</p></div><div id="abs1-4"><h4 class="inline">Setting:</h4><p>Paediatric and young adult diabetes clinics across 16 sites in the United Kingdom.</p></div><div id="abs1-5"><h4 class="inline">Participants:</h4><p>Newly diagnosed with type 1 diabetes and aged 12–18 years.</p></div><div id="abs1-6"><h4 class="inline">Eligibility criteria:</h4><p>Type 1 diabetes confirmed by islet autoantibody testing, within 100 days of first insulin injection, and with residual beta cell function (stimulated C-peptide level > 0.2 nmol/l).</p></div><div id="abs1-7"><h4 class="inline">Interventions:</h4><p>Ustekinumab at the highest approved doses or control (saline) subcutaneously at weeks 0, 4 and 12 and subsequently every 8 weeks to week 44 (seven doses).</p></div><div id="abs1-8"><h4 class="inline">Main outcome measures:</h4><p>Preservation of Mixed Meal Tolerance Test stimulated 2-hour insulin C-peptide area under the curve at week 52 as compared to control (saline) treatment by analysis of covariance adjusted for baseline parameters.</p></div><div id="abs1-9"><h4 class="inline">Randomisation:</h4><p>2 : 1 Remote computerised randomisation with minimisation by age and baseline C-peptide groups.</p></div><div id="abs1-10"><h4 class="inline">Blinding:</h4><p>Blinding of participants, investigators, laboratory and trial staff.</p></div><div id="abs1-11"><h4 class="inline">Numbers randomised:</h4><p>Seventy-two participants were randomised, 60% male, 18% aged 16–18 years.</p></div><div id="abs1-12"><h4 class="inline">Recruitment:</h4><p>Two hundred and eight potentially eligible patients were approached, and 88 patients were screened. Four participants were lost to follow-up (6%). Four participants withdrew from the treatment but attended the primary end-point assessment.</p></div><div id="abs1-13"><h4 class="inline">Numbers analysed:</h4><p>Six participants were missing baseline data for the primary analysis. The final analysable sample was <i>n</i> = 62.</p></div><div id="abs1-14"><h4 class="inline">Outcome:</h4><p>Ustekinumab was associated with a 49% higher endogenous stimulated insulin production than control at week 52 after adjustments for baseline factors [geometric ratio of ustekinumab to control was 1.49 (95% confidence interval 1.08 to 2.06; <i>p</i> = 0.02)].</p><p>Secondary analyses showed no difference in C-peptide at week 28 suggesting that the effect was ‘late’ or ‘delayed’. Ancillary analysis showed a significant reduction in activated T helper 17.1 T cells (<i>p</i> < 0.001) in the treatment group which was associated with C-peptide preservation from week 28 to week 52.</p></div><div id="abs1-15"><h4 class="inline">Harms:</h4><p>No severe adverse events were reported and there were no differences between ustekinumab and control groups in the proportion of participants overall experiencing mild (87% vs. 88%) or moderate (32% vs. 32%) events.</p></div><div id="abs1-16"><h4 class="inline">Limitations:</h4><p>Sensitivity analysis showed the primary end point to be robust to exclusion of small numbers of participants with some protocol deviations and extreme values in key covariates, but not to imputation of all missing data.</p></div><div id="abs1-17"><h4 class="inline">Conclusions:</h4><p>Ustekinumab appears to slow down the autoimmune process providing the first clinical trial evidence that interleukin 17-secreting T cells play a pathogenic role in type 1 diabetes. Alone, it is insufficient to halt the autoimmune process.</p></div><div id="abs1-18"><h4 class="inline">Future work:</h4><p>Replication of this result is ongoing in a trial with a similar design in Canada. If confirmed, consideration may be given to testing other drugs targeting the interleukin 17 pathway, using ustekinumab in combination with other agents or using it earlier in the disease pathway (preclinical disease) since it is so well tolerated and simple to use.</p></div><div id="abs1-19"><h4 class="inline">Study registration:</h4><p>Current Controlled Trials ISRCTN14274380.</p></div><div id="abs1-20"><h4 class="inline">Funding:</h4><p>This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (<a href="/books/n/ukeme1201/g1/?report=reader#g1-def29">NIHR</a> award ref: 16/36/01) and is published in full in <i>Efficacy and Mechanism Evaluation</i>; Vol. 12, No. 1. See the <a href="/books/n/ukeme1201/g1/?report=reader#g1-def29">NIHR</a> Funding and Awards website for further award information.</p></div></div><div itemprop="description"><h2>Plain language summary</h2><p>USTEK1D was a clinical trial of the immune therapy ustekinumab in teenagers (aged 12–18) who had been diagnosed in the previous 3 months with type 1 diabetes. The aim was to stop the loss of the body’s insulin-making cells. Ustekinumab was given subcutaneously (into the skin) at the start of the trial, 4 weeks later, and then every 8 weeks until week 44 (i.e. seven doses in total) and then patients were followed up at week 52. Forty-seven teenagers received ustekinumab and 25 received saltwater injections that looked the same as the medicine (the ‘control’ treatment).</p><p>The study showed that after 12 months, teenagers given ustekinumab produced 49% more insulin in their own bodies than those given the control. The treatment was very safe with no serious side effects. Laboratory studies confirmed that the ustekinumab treatment reduced the number of immune cells making the interleukin 17 protein. Interleukin 17-making immune cells are known to damage other cells. Teenagers with the greatest reduction in interleukin 17-making cells had the best protection in their insulin-making capacity. However, the treatment appeared to take up to 6 months to have an effect, and by that stage, over 40% of the insulin-making capacity had been lost. There were no differences in average blood glucose levels or low blood glucose episodes (which can lead to loss of consciousness) between the treatments.</p><p>We conclude that ustekinumab appears to slow down the autoimmune disease process in type 1 diabetes. The study also provides evidence that interleukin 17-making immune cells are important in causing type 1 diabetes. Ustekinumab had very few side effects. However, on its own, ustekinumab does not seem able to stop the autoimmune process altogether and a lot of insulin-making capacity is lost before it takes effect. For greater effect, future studies could combine ustekinumab with other treatments to protect insulin-making cells in type 1 diabetes.</p></div></div></div><div class="fm-sec"><div class="pmc_boxed-text-box fm-sec whole_rhythm"><h3>About the Series</h3><div class="half_rhythm"><div>Efficacy and Mechanism Evaluation</div></div><div class="half_rhythm"><div>ISSN (Electronic): 2050-4373</div></div></div><div><div id="n1-1"><h2>Article history</h2><p>The research reported in this issue of the journal was funded by the EME programme as award number 16/36/01. The contractual start date was in November 2017. The draft manuscript began editorial review in January 2024 and was accepted for publication in September 2024. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ manuscript and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this article.</p></div></div><p class="small">Last reviewed: January 2024; Accepted: September 2024.</p><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025 Carter <i>et al</i>.<p class="small">This work was produced by Carter <i>et al</i>. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: <a href="https://creativecommons.org/licenses/by/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">https://creativecommons.org/licenses/by/4.0/</a>. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.</p></div><div class="small"><span class="label">Bookshelf ID: NBK612279</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39999241" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">39999241</a></span>DOI: <a href="http://dx.crossref.org/10.3310/FQLN7416" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">10.3310/FQLN7416</a></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|